And one for the treatment of Gram+ skin infections.

We are confident that of Concept for Topical Antimicrobial Drug LytixarTM : completion of two Phase I / IIa clinical trialsThe Norwegian pharmaceutical company Lytix Biopharma announces the successful completion of two Phase I / IIa studies with the topical antimicrobial active LytixarTM – one for nasal decolonization MRSA / MSSA bacteria, and one for … [Read more…]